Overview

Detailed Summary

Lotus Eye Hospital & Institute Ltd is a renowned eye care hospital group situated in South India, specializing in super-specialty services related to ophthalmology.
The company operates seven centers across major cities, offering advanced eye care through cutting-edge technologies like LASIK and Zyoptix, backed by expert ophthalmologists.
Lotus Eye Hospital was the first in South East Asia to implement Epilasik technology and has consistently introduced advanced ophthalmic procedures.
It maintains a total bed capacity of 120 across its centers, focusing predominantly on outpatient and day-care surgeries.
The hospital's operations are characterized by high-tech equipments, ensuring top-tier eye care with a well-trained paramedical and administrative workforce.

Sector: Healthcare Services
Industry: Hospital
Market Cap: 233 Cr
Volatility: Low Risk
P/E Ratio: 358.5
Industry P/E: 60.2
PEG Ratio: 12.5
P/B Ratio: 3.8
52W High: 147.60
52W Low: 65.05

Sales CAGR

1Y: 2.80%
3Y: 8.40%
5Y: 4.09%
10Y: 5.30%

Profit CAGR

1Y: -74.57%
3Y: -37.20%
5Y: -7.03%
10Y: 24.78%

ROE

TTM: 1.11%
3Y: 4.37%
5Y: 4.32%
10Y: 3.05%

ROCE

TTM: 2.57%
3Y: 6.43%
5Y: 6.17%
10Y: 4.11%

Technicals

‌

Forecasts

Peers

Healthcare Healthcare Healthcare Services Hospital

Symbol	Watchlist	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
LOTUSEYE		111.60	233 Cr	358.49	3.84	0.00	1.11	2.57	0.91
AASHKA		60.00	180 Cr	74.15	1.81	0.00	1.13	2.34	2.08
HANNAH		75.50	170 Cr	20.66	1.81	0.00	14.43	15.98	7.88
ABATEAS		11.50	163 Cr	15.46	0.96	0.00	4.40	4.57	4.91
MAITREYA		155.90	122 Cr	762.31	4.56	0.00	0.52	4.98	0.33
FORTISMLR		52.44	104 Cr	22.96	3.03	0.00	13.19	14.48	12.21
SANGANI		41.20	75 Cr	39.58	2.07	0.00	5.09	6.48	3.76
Median: 7 Co.	—	60.00	163 Cr	39.58	2.07	0.00	4.40	4.98	3.76

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

Ask AI

Standalone Quarterly Results (in ₹ Crores)

Total Figures

QoQ Changes

Total Figures

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Sales	13	12	11	13	13	12	12	14	13	14
Expenses	11	10	10	11	12	11	12	12	12	13
Operating Profit	1.81	1.58	0.75	1.67	1.15	0.80	-0.17	1.48	0.78	0.65
OPM %	14.22	13.13	6.89	12.96	8.91	6.53	-1.48	10.95	5.98	4.80
Other Income	0.28	0.34	0.40	0.31	0.26	0.22	0.52	0.19	0.27	0.24
Interest	0.01	0.04	0.03	0.06	0.08	0.13	0.09	0.12	0.12	0.29
Depreciation	0.89	0.98	1.12	1.06	1.23	1.31	-0.58	0.82	0.85	0.98
Profit Before Tax	1.19	0.90	0.01	0.86	0.11	-0.43	0.84	0.73	0.07	-0.38
Tax %	28.57	26.67	-200.00	26.74	9.09	44.19	70.24	26.03	-57.14	28.95
Net Profit	0.85	0.66	0.02	0.62	0.10	-0.24	0.25	0.54	0.12	-0.26
EPS in Rs	0.41	0.32	0.01	0.30	0.05	-0.11	0.12	0.26	0.06	-0.13

Standalone Profit Loss (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	34	38	38	41	32	39	47	48	50	50
Expenses	31	34	35	37	29	33	39	42	46	47
Operating Profit	3.24	4.22	3.07	3.81	3.55	5.85	7.59	6.53	3.43	3.26
OPM %	9.55	11.10	8.00	9.41	10.96	15.03	16.13	13.55	6.93	6.50
Other Income	0.68	0.91	0.68	0.21	0.83	0.88	1.14	1.31	1.31	1.19
Interest	0.06	0.05	0.06	0.07	0.06	0.13	0.10	0.10	0.36	0.42
Depreciation	3.44	3.37	3.06	2.50	2.33	2.50	2.98	3.73	3.01	2.78
Profit Before Tax	0.42	1.70	0.63	1.46	1.99	4.09	5.65	4.01	1.38	1.25
Tax %	-6.14	-2.60	-12.77	26.86	21.29	27.10	27.86	27.39	46.53	48.00
Net Profit	0.44	1.75	0.71	1.06	1.57	2.98	4.08	2.91	0.74	0.65
EPS in Rs	0.21	0.84	0.33	0.51	0.76	1.44	1.96	1.41	0.36	0.31
Dividend Payout %	238.10	59.52	0.00	0.00	66.67	34.72	25.51	0.00	0.00	—

Standalone Balance Sheet (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	21	21	21	21	21	21	21	21	21	21
Reserves	29	29	30	29	30	32	34	37	39	39
Borrowings	0.48	0.30	0.09	0.09	0.00	0.40	1.24	0.67	1.11	3.43
Other Liabilities	4.86	4.59	7.48	6.31	6.85	6.13	5.76	4.94	6.11	6.14
Total Liabilities	55	55	58	57	58	59	62	63	67	70
Fixed Assets	44	41	43	44	43	41	44	44	49	54
CWIP	0.42	0.65	0.29	0.29	0.00	0.00	0.00	0.00	0.08	0.00
Investments	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Assets	11	13	15	12	15	19	18	19	18	16
Total Assets	55	55	58	57	58	59	62	63	67	70

Standalone Cash Flows (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	3.38	2.97	5.78	4.20	4.97	2.73	4.41	4.39	5.68	2.70
Cash from Investing Activity	-0.85	-1.06	-3.86	-4.01	-0.68	0.49	-3.94	-2.19	-4.63	-6.13
Cash from Financing Activity	-0.58	-0.25	-1.51	-1.41	0.13	-0.32	-1.58	-1.71	-3.40	-1.60
Net Cash Flow	1.96	1.66	0.41	-1.22	4.42	2.90	-1.10	0.49	-2.35	-5.03

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Promoters	58.43%	57.58%	56.58%	41.40%	40.24%	40.03%	40.14%	40.22%	40.39%	40.64%	39.67%	40.14%
FIIs	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.01%	0.00%
DIIs	0.00%	0.00%	0.00%	0.00%	0.01%	0.03%	0.04%	0.04%	0.03%	0.02%	2.46%	0.02%
Public	41.57%	42.42%	43.42%	58.60%	59.75%	59.94%	59.82%	59.74%	59.58%	59.33%	57.86%	59.84%
Total Shareholders	7,425	7,660	8,314	12,502	11,759	12,514	11,734	11,508	11,121	10,777	10,241	9,939

Market Transactions

Unlock more with professional

Real-time bulk & block deal transactions
Export transaction data for analysis

Projection

Documents

Presentations

Concalls

Reports

Presentations

Investor Presentation

Q1 FY22

Investor Presentation

Q3 FY21

Actions

Action Type

‌
‌

Announcements

Last 7 days

Newest

Sentiment

Substantial Acquisition

3 days ago

Promoter Sangeetha Sundaramoorthy raises stake in Lotus Eye to 35.01%

Sangeetha Sundaramoorthy (promoter) acquired 1,428,571 equity shares (6.8693%) in Lotus Eye Hospital And Institute Ltd via inter‑se transfer on 27.02.2026, increasing her holding to 7,280,472 shares (35.0084%).

Acquisition disclosure

3 days ago

Acquirer Sangeetha Sundaramoorthy increases stake in Lotus Eye Hospital

Disclosure: Sangeetha Sundaramoorthy acquired 14,28,571 equity shares (6.8693%) via inter‑se transfer on 27‑Feb‑2026, raising her holding from 58,51,901 (28.1391%) to 72,80,472 (35.0084%) in Lotus Eye Hospital & Institute Ltd.

AI Mode

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.

Ask AI

Frequently Asked Questions about Lotus Eye Hospital & Institute Ltd

Lotus Eye Hospital & Institute Ltd (LOTUSEYE) is currently trading at 112.05 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Lotus Eye Hospital & Institute Ltd is a renowned eye care hospital group situated in South India, specializing in super-specialty services related to ophthalmology. The company operates seven centers across major cities, offering advanced eye care through cutting-edge technologies like LASIK and Zyoptix, backed by expert ophthalmologists. Lotus Eye Hospital was the first in South East Asia to implement Epilasik technology and has consistently introduced advanced ophthalmic procedures. It maintains a total bed capacity of 120 across its centers, focusing predominantly on outpatient and day-care surgeries. The hospital's operations are characterized by high-tech equipments, ensuring top-tier eye care with a well-trained paramedical and administrative workforce.

Over the past 52 weeks, Lotus Eye Hospital & Institute Ltd has traded between a low of ₹65.05 and a high of ₹147.60. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Lotus Eye Hospital & Institute Ltd has a market capitalization of approximately 233.02. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Lotus Eye Hospital & Institute Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 358.49 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 233.02 Cr, Lotus Eye Hospital & Institute Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Lotus Eye Hospital & Institute Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Lotus Eye Hospital & Institute Ltd is 358.49. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Lotus Eye Hospital Institute Ltd

Stock Summary and Key Metrics

Investment Checklist

Investment Checklist

Overview

Financial Ratios

Technicals

Forecasts

Peers

Price Chart Comparison